Diabetic macular oedema (DME)

This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.

Diabetic Macular Oedema (DME)

EYLEA 8mg (aflibercept 114.3 mg/ml) is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DME).

For those who want flexibity to optimise patient intervals to Q16 and beyond

Save sight

whilst minimising treatment burden

Flexibility to extend treatment

intervals as far as Q24

Suppress VEGF

with a safety profile comparable to EYLEA 2mg.

PHOTON

Optimise vision whilst minimising burden

Primary endpoint: mean change in BCVA from baseline to Week 48 (non-inferiority)
Optional 1-year open-label extension until Week 156

In PHOTON, lasting BCVA gains from baseline were non-inferior with EYLEA 8 mg vs EYLEA 2 mg and maintained through Week 156, with as few as 10 injections over 3 years*

*eFAS, observed cases.

Week 156

Extend treatment intervals for your eligible DME patients

At Week 156, >8 out of 10 patients in the EYLEA 2Q8→8 mg group achieved a last completed dosing interval of ≥Q12 at Week 156, within a year of switching (PHOTON)*

PHOTON - Last completed treatment intervals

Could having more patients reach longer intervals help streamline your clinic?

*Patients completing Week 156: 8Q12/8Q16 n=152; 2Q8→8 mg n=58.

At Week 156, ~5 in 10 patients were last assigned to ≥Q20 in the EYLEA 8Q12/8Q16 group*

Adapted from Do D. 2024 & Brown DM. 2025

*Patients who were randomised to the 8Q12 or 8Q16 groups at the beginning of the PHOTON study and continued treatment with EYLEA 8 mg through the PHOTON extension study.

^†eFAS, patients completing Week 156.

Week 96

Flexibility to extend treatment intervals for eligible patients across your DME clinic

In PHOTON, ~9 out of 10 patients achieved a last assigned dosing interval of ≥Q16 at Week 96^*

^{* Patients completing Week 96: 8Q12 n=256; 8Q16 n=139.}

Flexibility to extend treatment intervals beyond expectations

The first and only anti-VEGF for DME that allows for extension to treatment intervals of Q24 after reaching Q16^*

^{* Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q24 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology}
^{† Patients completing Week 96: 8Q12 n=256; 8Q16 n=139.}

Week 48

Flexibility to extend treatment intervals for eligible DME patients

In PHOTON, ~9 out of 10 patients maintained 16-week treatment intervals from baseline through Week 48^*

^{* Patients completing Week 48: 2Q8 n=157; 8Q12 n=300; 8Q16 n=156.}

Discover more about how you can meet the needs of your eligible nAMD patients with EYLEA 8mg

Dosing

Discover proactive dosing in nAMD and DME

Mechanism of Action (MoA)

Discover more about the MoA of EYLEA 8mg

Abbreviations

2Q8, 2mg every 8 weeks; 8Q12, 8mg every 12 weeks; 8Q16, 8mg every 16 weeks; AE, adverse event; APTC, Anti-Platelet Trialists’ Collaboration; BCVA, best-corrected visual acuity; BMI, body mass index; CI, confidence interval; CRT, central retinal thickness; DME, diabetic macular oedema; DRM, dosing regimen modification; DRSS, diabetic retinopathy severity study; eFAS, extension phase full analysis set; eSAF, extension safety analysis set; ETDRS, Early Treatment of Diabetic Retinopathy Study; FAS, full analysis set; ICE, intercurrent event; IOI, intraocular inflammation; IOP, intraocular pressure; LS, least squares; MMRM, mixed model for repeated measurements; MoA, mechanism of action; nAMD, neovascular (wet) age-related macular degeneration; Q4, every 4 weeks; Q8, every 8 weeks; Q12, every 12 weeks; Q16, every 16 weeks; Q20, every 20 weeks; Q24, every 24 weeks; SAE, serious adverse event; SAF, safety analysis set; SD, standard deviation; SmPC, Summary of Product Characteristics; T&E, treat and extend; TEAE, treatment-emergent adverse event; VEGF, vascular endothelial growth factor.

PP-EYL_8mg-IE-0153-2 | August 2026

References

1
EYLEA® 114.3 mg/mL Summary of Product Characteristics.
2
Do D. Aflibercept 8 mg for diabetic macular edema: 48-week results from the Phase 2/3 PHOTON trial. ARVO. 23–27 April 2023. Palo Alto, USA. Oral presentation.
3
Wykoff CC. Aflibercept 8 mg for diabetic macular edema: 96-week results from the Phase 2/3 PHOTON trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
4
Do D. Aflibercept 8mg in DME: Key results from the PHOTON extension study. AAO. 18–21 October 2024. Chicago, USA. Oral presentation.
5
Bayer Data on File. PP-EYL_8mg-GB-0741. October 2025.
6
Brown DM. Aflibercept 8 mg in diabetic macular edema: 156-week results from the PHOTON extension study. Macula Society 2025. 12–15 February 2025. Florida, USA. Oral presentation.
7
Brown DM. Intravitreal aflibercept injection 8 mg for DME: 48-week results from the Phase 2/3 PHOTON trial. Retina Society. 2–5 November 2022. Pasadena, USA. Oral presentation.
8
ClinicalTrials.gov. NCT04429503. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT04429503. Accessed: December 2025
9
Brown DM, et al. Lancet. 2024;403(10432):1153–1163.
10
Do D. Aflibercept 8 mg for diabetic macular edema: 96-week results from the Phase 2/3 PHOTON trial. AAO. 3–6 November 2023. San Francisco, USA. Oral presentation.